| Texto completo | |
| Autor(es): Mostrar menos - |
Spadari, Cristina de Castro
;
Esposito, Fernanda Ribeiro dos Santos
;
Sano, Elder
;
Aires, Caroline Cotrim
;
Conselheiro, Juliana Amorim
;
Barone, Gisely Toledo
;
de Oliveira, Danielle Bruna Leal
;
Durigon, Edison Luiz
;
Sampaio, Jorge M.
;
Lincopan, Nilton
;
Ishida, Kelly
Número total de Autores: 11
|
| Tipo de documento: | Artigo Científico |
| Fonte: | Canadian Journal of Microbiology; v. 71, p. 5-pg., 2025-11-01. |
| Resumo | |
Coinfection and secondary infection by fungi in patients with viral pulmonary infection, especially SARS-CoV-2, are important factors that worsen the prognosis and are associated to increased death rates. This work aims to report the prevalence of Candida isolates in bronchoalveolar and nasopharyngeal samples from suspected COVID-19 patients in the first-second pandemic waves and their antifungal resistance profile. From 2321 patients, 29.04% were diagnosed with SARS-CoV-2 infection. The yeast isolation rate of 6.97% (47/674) from positive SARS-CoV-2 was statistically higher than 4.43% (73/1647) from negative SARS-CoV-2 patients (p = 0.0177). Among yeasts, the most prevalent species was Candida albicans (63/120), with four being azole-resistant isolates (6.35%); however, other emerging and less susceptible species were also isolated, such as Candida guilliermondii (11), Candida glabrata (5), Candida lusitaniae (4), Candida krusei (1), and Candida norvegensis (1). Here, we highlighted Candida prevalence in respiratory tract, emphasizing the relevance for surveillance in SARS-CoV-2/COVID patients for improvement of management as well as patient outcomes. (AU) | |
| Processo FAPESP: | 20/06409-1 - Avaliação da resposta imune humoral e da resposta inflamatória em pacientes com diagnóstico confirmado de COVID-19 no Hospital Sírio Libanês e correlação com a severidade da doença |
| Beneficiário: | Edison Luiz Durigon |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |
| Processo FAPESP: | 18/12149-2 - Nanopartículas como carreadores de miltefosina para tratamento de meningite criptocócica. |
| Beneficiário: | Cristina de Castro Spadari |
| Modalidade de apoio: | Bolsas no Brasil - Pós-Doutorado |